EC 3.4.21.73 - u- plasminogen activator

3D structures of EC 3.4.21.73 - u-plasminogen activator in Protein Data Bank

updated: 6 January 2022, 2:15

1. 1c5w: Structural Basis for Selectivity of a Small Molecule, S1- Binding, Sub-micromolar Inhibitor of Urokinase Type Plasminogen Activator
2. 1c5x: Structural Basis for Selectivity of a Small Molecule, S1- Binding, Sub-micromolar Inhibitor of Urokinase Type Plasminogen Activator
3. 1c5y: Structural Basis for Selectivity of a Small Molecule, S1- Binding, Sub-micromolar Inhibitor of Urokinase Type Plasminogen Activator
4. 1c5z: Structural Basis for Selectivity of a Small Molecule, S1- Binding, Sub-micromolar Inhibitor of Urokinase Type Plasminogen Activator
5. 1ejn: Urokinase Plasminogen Activator B-chain Inhibitor Complex
6. 1f5k: Urokinase Plasminogen Activator B-chain-benzamidine Complex
7. 1f5l: Urokinase Plasminogen Activator B-chain-amiloride Complex
8. 1f92: Urokinase Plasminogen Activator B Chain-uki-1d Complex
9. 1fv9: Crystal Structure of Human Microurokinase in Complex with 2- Amino-5-hydroxy-benzimidazole
10. 1gi7: A Novel Serine Protease Inhibition Motif Involving a Multi- Centered Short Hydrogen Bonding Network at The Active Site
11. 1gi8: A Novel Serine Protease Inhibition Motif Involving a Multi- Centered Short Hydrogen Bonding Network at The Active Site
12. 1gi9: A Novel Serine Protease Inhibition Motif Involving a Multi- Centered Short Hydrogen Bonding Network at The Active Site
13. 1gj7: Engineering Inhibitors Highly Selective for The S1 Sites of Ser190 Trypsin-like Serine Protease Drug Targets
14. 1gj8: Engineering Inhibitors Highly Selective for The S1 Sites of Ser190 Trypsin-like Serine Protease Drug Targets
15. 1gj9: Engineering Inhibitors Highly Selective for The S1 Sites of Ser190 Trypsin-like Serine Protease Drug Targets
16. 1gja: Engineering Inhibitors Highly Selective for The S1 Sites of Ser190 Trypsin-like Serine Protease Drug Targets
17. 1gjb: Engineering Inhibitors Highly Selective for The S1 Sites of Ser190 Trypsin-like Serine Protease Drug Targets
18. 1gjc: Engineering Inhibitors Highly Selective for The S1 Sites of Ser190 Trypsin-like Serine Protease Drug Targets
19. 1gjd: Engineering Inhibitors Highly Selective for The S1 Sites of Ser190 Trypsin-like Serine Protease Drug Targets
20. 1lmw: Lmw U-pa Structure Complexed with Egrcmk (glu-gly-arg Chloromethyl Ketone)
21. 3mhw: The Complex Crystal Structure of Urokianse and 2- Aminobenzothiazole
22. 3m61: Crystal Structure of Complex of Urokinase and a Upain-1 VARIANT(W3A) in Ph4.6 Condition
23. 3laq: Structure-based Engineering of Species Selectivity in The Upa-upar Interaction
24. 1o3p: Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-directed Serine Protease Inhibitors
25. 1o5a: Dissecting and Designing Inhibitor Selectivity Determinants at The S1 Site Using an Artificial Ala190 Protease (ala190 Upa)
26. 1o5b: Dissecting and Designing Inhibitor Selectivity Determinants at The S1 Site Using an Artificial Ala190 Protease (ala190 Upa)
27. 1o5c: Dissecting and Designing Inhibitor Selectivity Determinants at The S1 Site Using an Artificial Ala190 Protease (ala190 Upa)
28. 3kid: The Crystal Structures of 2-aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator
29. 3khv: Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(aminomethyl) Benzoic Acid and 4- (aminomethyl-phenyl)-methanol
30. 3kgp: Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(aminomethyl) Benzoic Acid and 4- (aminomethyl-phenyl)-methanol
31. 1owd: Substituted 2-naphthamidine Inhibitors of Urokinase
32. 1owe: Substituted 2-naphthamidine Inhibitors of Urokinase
33. 1owh: Substituted 2-naphthamidine Inhibitors of Urokinase
34. 1owi: Substituted 2-naphthamidine Inhibitors of Urokinase
35. 1owj: Substituted 2-naphthamidine Inhibitors of Urokinase
36. 1owk: Substituted 2-naphthamidine Inhibitors of Urokinase
37. 3ig6: Low Molecular Weigth Human Urokinase Type Plasminogen Activator 2-[6-(3'-aminomethyl-biphenyl-3-yloxy)-4-(3- Dimethylamino-pyrrolidin-1-yl)-3,5-difluoro-pyridin-2- Yloxy]-4-dimethylamino-benzoic Acid Complex
38. 1sc8: Urokinase Plasminogen Activator B-chain-j435 Complex
39. 1sqa: Substituted 2-naphthamidine Inhibitors of Urokinase
40. 1sqo: Substituted 2-naphthamidine Inhibitors of Urokinase
41. 1sqt: Substituted 2-naphthamidine Inhibitors of Urokinase
42. 1u6q: Substituted 2-naphthamadine Inhibitors of Urokinase
43. 1vj9: Urokinase Plasminogen Activator B-chain-jt464 Complex
44. 1vja: Urokinase Plasminogen Activator B-chain-jt463 Complex
45. 1w0z: Urokinase Type Plasminogen Activator
46. 1w10: Urokinase Type Plasminogen Activator
47. 1w11: Urokinase Type Plasminogen Activator
48. 1w12: Urokinase Type Plasminogen Activator
49. 1w13: Urokinase Type Plasminogen Activator
50. 1w14: Urokinase Type Plasminogen Activator
51. 2vnt: Urokinase-type Plasminogen Activator Inhibitor Complex with a 1-(7-sulphoamidoisoquinolinyl)guanidine
52. 2viw: Fragment-based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-type Plasminogen Activator
53. 2viv: Fragment-based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-type Plasminogen Activator
54. 2viq: Fragment-based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-type Plasminogen Activator
55. 2vip: Fragment-based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-type Plasminogen Activator
56. 2vio: Fragment-based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-type Plasminogen Activator
57. 2vin: Fragment-based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-type Plasminogen Activator
58. 2r2w: Urokinase Plasminogen Activator B-chain-gppe Complex
59. 2o8w: Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in Complex with Inhibitors
60. 2o8u: Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in Complex with Inhibitors
61. 2o8t: Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in Complex with Inhibitors
62. 6ag9: Crystal Structure of Upa in Complex with 3,5-bis(azanyl)-6-(1- Benzofuran-2-yl)-n-carbamimidoyl-pyrazine-2- Carboxamide
63. 6ag7: The Crystal Structure of Upa in Complex with Hma-55f
64. 6ag3: Crystal Structure of Upa in Complex with 3,5-bis(azanyl)-n- Carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide
65. 6ag2: Upa-hma
66. 6a8n: The Crystal Structure of Mupain-1-ig-2 in Complex with Mupa-spd at Ph8.5
67. 6a8g: The Crystal Structure of Mupain-1-ig in Complex with Mupa-spd at Ph8.5
68. 2fd6: Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an Anti-upar Antibody at 1.9 a
69. 5zc5: Upa-nu-09f
70. 5zaj: Upa-31f
71. 5zah: Upa-bb2-30f
72. 5zag: Upa-bb2-94f
73. 5zaf: Upa-bb2-28f
74. 5zae: Upa-6f-hma
75. 5za9: Upa-bb2-50f
76. 5za8: Upa-bb2-27f
77. 5za7: Upa-hma
78. 5z1c: The Crystal Structure of Upa in Complex with 4-iodobenzylamine at Ph7.4
79. 2i9a: Crystal Structure of The Free Aminoterminal Fragment of Urokinase Type Plasminogen Activator (atf)
80. 2i9b: Crystal Structure of Atf-urokinase Receptor Complex
81. 6l05: Crystal Structure of UPA_H99Y in Complex with 50f
82. 6l04: Crystal Structure of UPA_H99Y in Complex with 31f
83. 3pb1: Crystal Structure of a Michaelis Complex between Plasminogen Activator Inhibitor-1 and Urokinase-type Plasminogen Activator
84. 6jyq: Crystal Structure of UPA_H99Y in Complex with 3-azanyl-5-(azepan-1- Yl)-n-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide
85. 6jyp: Crystal Structure of UPA_H99Y in Complex with 3-azanyl-5-(azepan-1- Yl)-n-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide
86. 3mwi: The Complex Crystal Structure of Urokianse and 5-nitro-1h-indole-2- Amidine
87. 3ox7: The Crystal Structure of Upa Complex with Peptide Inhibitor Mh027 at Ph4.6
88. 3oy5: The Crystal Structure of Upa Complex with Peptide Inhibitor Mh027 at Ph7.4
89. 3oy6: The Crystal Structure of Upa Complex with Peptide Inhibitor Mh036 at Ph4.6
90. 3qn7: Potent and Selective Bicyclic Peptide Inhibitor (uk18) of Human Urokinase-type Plasminogen Activator(upa)
91. 3u73: Crystal Structure of Stabilized Human Upar Mutant in Complex with Atf
92. 6nmb: Tranexamic Acid Is an Active Site Inhibitor of Urokinase Plasminogen Activator
93. 4fu7: Crystal Structure of The Urokinase
94. 4fu8: Crystal Structure of The Urokinase
95. 4fu9: Crystal Structure of The Urokinase
96. 4fub: Crystal Structure of The Urokinase
97. 4fuc: Crystal Structure of The Urokinase
98. 4fud: Crystal Structure of The Urokinase
99. 4fue: Crystal Structure of The Urokinase
100. 4fuf: Crystal Structure of The Urokinase
101. 4fug: Crystal Structure of The Urokinase
102. 4fuh: Crystal Structure of The Urokinase
103. 4fui: Crystal Structure of The Urokinase
104. 4fuj: Crystal Structure of The Urokinase
105. 4dva: The Crystal Structure of Human Urokinase-type Plasminogen Activator Catalytic Domain
106. 4dw2: The Crystal Structure of Upa in Complex with The Fab Fragment of Mab- 112
107. 4gly: Human Urokinase-type Plasminogen Activator Upa in Complex with The Two-disulfide Bridge Peptide Uk504
108. 4jk5: Human Urokinase-type Plasminogen Activator (upa) in Complex with a Bicyclic Peptide Inhibitor (uk18-d-ser)
109. 4jk6: Human Urokinase-type Plasminogen Activator (upa) in Complex with a Bicyclic Peptide Inhibitor (uk18-d-aba)
110. 4h42: Synthesis of a Weak Basic Upa Inhibitor and Crystal Structure of Complex with Upa
111. 4k24: Structure of Anti-upar Fab Atn-658 in Complex with Upar
112. 4mnv: Crystal Structure of Bicyclic Peptide Uk729 Bound as an Acyl-enzyme Intermediate to Urokinase-type Plasminogen Activator (upa)
113. 4mnw: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk749
114. 4mnx: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk811
115. 4mny: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk903
116. 4os1: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk601 (bicyclic 1)
117. 4os2: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk602 (bicyclic 1)
118. 4os4: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk603 (bicyclic 1)
119. 4os5: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk603 (bicyclic 2)
120. 4os6: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk604 (bicyclic 2)
121. 4os7: Crystal Structure of Urokinase-type Plasminogen Activator (upa) Complexed with Bicyclic Peptide Uk607 (bicyclic)
122. 5yc7: The Crystal Structure of Upa in Complex with 4-bromobenzylamirne at Ph7.4
123. 5yc6: The Crystal Structure of Upa in Complex with 4-bromobenzylamirne at Ph4.6
124. 5xg4: Crystal Structure of Upa in Complex with Quercetin
125. 5wxt: Crystal Structure of UPA-S195A in Complex with S2444
126. 5wxs: Crystal Structure of Upa in Complex with S2444
127. 5wxr: Crystal Structure of Upa in Complex with UPAIN-2-4-W3A
128. 5wxq: Crystal Structure of Upa in Complex with Upain-2-4
129. 5wxp: Crystal Structure of Upa in Complex with UPAIN-2-3-W3A
130. 5wxo: Crystal Structure of Upa in Complex with UPAIN-2-2-W3A
131. 5wxf: Crystal Structure of Upa in Complex with Upain-2-2
132. 5lhs: The Ligand Free Catalytic Domain of Murine Urokinase-type Plasminogen Activator
133. 5lhr: The Catalytic Domain of Murine Urokinase-type Plasminogen Activator in Complex with The Active Site Binding Inhibitory Nanobody Nb22
134. 5lhq: The Egr-cmk Active Site Inhibited Catalytic Domain of Murine Urokinase-type Plasminogen Activator in Complex with The Allosteric Inhibitory Nanobody Nb7
135. 5lhp: The P-aminobenzamidine Active Site Inhibited Catalytic Domain of Murine Urokinase-type Plasminogen Activator in Complex with The Allosteric Inhibitory Nanobody Nb7
136. 5lhn: The Catalytic Domain of Murine Urokinase-type Plasminogen Activator in Complex with The Allosteric Inhibitory Nanobody Nb7
137. 5hgg: Crystal Structure of Upa in Complex with a Camelid-derived Antibody Fragment
138. 6xvd: Crystal Structure of Complex of Urokinase and a Upain-1 VARIANT(W3F) in Ph7.4 Condition
139. 4zks: The Crystal Structure of UPAIN-1-W3A in Complex with Inactive Upa (UPA-S195A) at Ph7.4
140. 4zkr: The Crystal Structure of UPAIN-1-W3A in Complex with Upa at Ph9.0
141. 4zko: The Crystal Structure of UPAIN-1-W3A in Complex with Upa at Ph7.4
142. 4zkn: The Crystal Structure of UPAIN-1-W3A in Complex with Upa at Ph5.5
143. 4zhm: The Crystal Structure of Mupain-1--16-ig in Complex with Murinised Human Upa at Ph7.4
144. 4zhl: The Crystal Structure of Mupain-1-ig in Complex with Murinised Human Upa at Ph7.4
145. 4x1n: The Crystal Structure of Mupain-1-16 in Complex with Murinised Human Upa at Ph7.4
146. 4x1q: The Crystal Structure of Mupain-1 in Complex with Murinised Human Upa at Ph7.4
147. 4x1r: The Crystal Structure of Mupain-1-12 in Complex with Murinised Human Upa at Ph7.4
148. 4x0w: The Crystal Structure of Mupain-1-17 in Complex with Murinised Human Upa
149. 4x1p: The Crystal Structure of Mupain-1-17 in Complex with Murinised Human Upa at Ph4.6
150. 4x1s: The Crystal Structure of MUPAIN-1-16-D9A in Complex with Murinised Human Upa at Ph7.4
151. 4xsk: Structure of Paitrap, an Upa Mutant
152. 7dzd: Crystal Structure of Upa in Complex with Cleaved Camostat